EdiTy Therapeutics
EdiTy Therapeutics19
About
What does EdiTy Therapeutics do?
EdiTy Therapeutics has developed a first-ever immune cell delivery technology that uses engineered immune cells as natural couriers for precision therapeutics. Their AI-powered platform engineers therapeutic proteins and optimizes them for targeted delivery through the immune system to diseased tissues, enabling new modalities for intracellular therapy. The company is initiating an investigational clinical program to increase the efficacy of CAR T therapy in solid tumors.
What is EdiTy Therapeutics's revenue?
StartupHub estimates EdiTy Therapeutics's annual revenue at $2.5M (range $1.5M to $4.3M, 64% confidence), based on comparable companies in the sector.
When was EdiTy Therapeutics founded?
EdiTy Therapeutics was founded in 2020.
What industry does EdiTy Therapeutics operate in?
EdiTy Therapeutics operates in Life Sciences, Immunology, Biotech, Genome Editing, Drug Discovery, Gene Therapy.
How many employees does EdiTy Therapeutics have?
EdiTy Therapeutics has approximately 16 people on record.
Galatek develops AI-driven automation solutions for life sciences laboratories and advanced semiconductor manufacturing, focusing on precision and reproducibility.
Digital batch record software for pharmaceutical and biotech manufacturing.
Biotalent is a platform that streamlines biotech hiring by connecting qualified candidates with job opportunities and providing hiring teams with tools for efficient candidate review.
AI-powered platform accelerating biological research and drug discovery.
A healthcare and life sciences consulting firm leveraging AI and data analytics for strategic solutions.
Empowering Life Science Entrepreneurs for Innovative Healthcare Solutions.
An entrant is a company tagged Life Sciences whose domain was first registered in the window, counted from registry records in the StartupHub directory. Registry detection runs two to three weeks behind registration, so recent weeks are a floor.
No comments yet. Be the first to share your take.